BioCentury | Jun 14, 2019
Clinical News

June 13 Clinical Quick Takes: Roche's Gazyva meets in Phase II for lupus; plus Boehringer/Lilly, Savara and more

...encapsulating rapamycin. Resolve's autoimmune therapy reduces fatigue in Phase II Sjögren’s trial Also at EULAR, Resolve Therapeutics LLC...
...Trazenta, linagliptin (BI 1356) Boehringer Ingelheim GmbH Bone Therapeutics S.A. Eli Lilly and Co. Follica Inc. Idorsia Ltd. Nektar Therapeutics PureTech Health plc Resolve Therapeutics LLC Roche Savara...
BioCentury | Aug 17, 2017
Finance

Built to purpose

...licensing agreement in 2016, also signed licensing deal with GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) in 2017 Resolve Therapeutics LLC...
BioCentury | Feb 22, 2016
Clinical News

RSLV-132: Phase I data

...other preclinical compounds to treat SLE and other autoimmune diseases (see BioCentury, March 4, 2013). Resolve Therapeutics LLC...
BioCentury | Aug 11, 2014
Clinical News

RSLV-132: Phase II started

...exercisable after completion of the Phase II trial in SLE (see BioCentury, March 4, 2013). Resolve Therapeutics LLC...
BioCentury | Mar 24, 2014
Clinical News

RSLV-132: Phase I started

...exercisable after completion of the Phase IIa trial in SLE (see BioCentury, March 4, 2013). Resolve Therapeutics LLC...
BioCentury | Mar 4, 2013
Company News

Resolve Therapeutics, Takeda deal

...composed of cellular debris, including autoantibodies and nucleic acids. Fenwick & West LLP advised Resolve. Resolve Therapeutics LLC...
BioCentury | Mar 1, 2013
Company News

Resolve grants Takeda option for autoimmune compounds

Resolve Therapeutics LLC (Seattle, Wash.) granted Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) an exclusive option to license worldwide rights to develop and commercialize preclinical compounds from Resolve to treat systemic lupus erythematosus (SLE) and other autoimmune...
BioCentury | Nov 5, 2012
Financial News

Resolve Therapeutics completes venture financing

Resolve Therapeutics LLC , Seattle, Wash. Business: Autoimmune Date completed: 11/1/12 Type: Venture financing Raised: $5.8 million Investors: New Science Ventures; WRF Capital; Easton Capital WIR Staff...
BioCentury | Jul 25, 2011
Emerging Company Profile

Resolve: Early answers, early exits

...U.K. Bristol-Myers Squibb Co. (NYSE:BMY), New York, N.Y. Genentech Inc. , South San Francisco, Calif. Resolve Therapeutics LLC...
...Seattle, Wash. Roche (SIX:ROG; OTCQX:RHHBY), Basel, Switzerland University of Washington , Seattle, Wash. Sidebars Resolve Therapeutics LLC...
BioCentury | May 23, 2011
Financial News

Resolve Therapeutics completes venture financing

...5/17/11 Type: Venture financing Raised: $2 million Investors: New Science Ventures; Easton Capital Investment Note: Resolve Therapeutics...
Items per page:
1 - 10 of 12
BioCentury | Jun 14, 2019
Clinical News

June 13 Clinical Quick Takes: Roche's Gazyva meets in Phase II for lupus; plus Boehringer/Lilly, Savara and more

...encapsulating rapamycin. Resolve's autoimmune therapy reduces fatigue in Phase II Sjögren’s trial Also at EULAR, Resolve Therapeutics LLC...
...Trazenta, linagliptin (BI 1356) Boehringer Ingelheim GmbH Bone Therapeutics S.A. Eli Lilly and Co. Follica Inc. Idorsia Ltd. Nektar Therapeutics PureTech Health plc Resolve Therapeutics LLC Roche Savara...
BioCentury | Aug 17, 2017
Finance

Built to purpose

...licensing agreement in 2016, also signed licensing deal with GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) in 2017 Resolve Therapeutics LLC...
BioCentury | Feb 22, 2016
Clinical News

RSLV-132: Phase I data

...other preclinical compounds to treat SLE and other autoimmune diseases (see BioCentury, March 4, 2013). Resolve Therapeutics LLC...
BioCentury | Aug 11, 2014
Clinical News

RSLV-132: Phase II started

...exercisable after completion of the Phase II trial in SLE (see BioCentury, March 4, 2013). Resolve Therapeutics LLC...
BioCentury | Mar 24, 2014
Clinical News

RSLV-132: Phase I started

...exercisable after completion of the Phase IIa trial in SLE (see BioCentury, March 4, 2013). Resolve Therapeutics LLC...
BioCentury | Mar 4, 2013
Company News

Resolve Therapeutics, Takeda deal

...composed of cellular debris, including autoantibodies and nucleic acids. Fenwick & West LLP advised Resolve. Resolve Therapeutics LLC...
BioCentury | Mar 1, 2013
Company News

Resolve grants Takeda option for autoimmune compounds

Resolve Therapeutics LLC (Seattle, Wash.) granted Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) an exclusive option to license worldwide rights to develop and commercialize preclinical compounds from Resolve to treat systemic lupus erythematosus (SLE) and other autoimmune...
BioCentury | Nov 5, 2012
Financial News

Resolve Therapeutics completes venture financing

Resolve Therapeutics LLC , Seattle, Wash. Business: Autoimmune Date completed: 11/1/12 Type: Venture financing Raised: $5.8 million Investors: New Science Ventures; WRF Capital; Easton Capital WIR Staff...
BioCentury | Jul 25, 2011
Emerging Company Profile

Resolve: Early answers, early exits

...U.K. Bristol-Myers Squibb Co. (NYSE:BMY), New York, N.Y. Genentech Inc. , South San Francisco, Calif. Resolve Therapeutics LLC...
...Seattle, Wash. Roche (SIX:ROG; OTCQX:RHHBY), Basel, Switzerland University of Washington , Seattle, Wash. Sidebars Resolve Therapeutics LLC...
BioCentury | May 23, 2011
Financial News

Resolve Therapeutics completes venture financing

...5/17/11 Type: Venture financing Raised: $2 million Investors: New Science Ventures; Easton Capital Investment Note: Resolve Therapeutics...
Items per page:
1 - 10 of 12